Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2009 - 2026)

Alnylam Pharmaceuticals has reported Free Cash Flow for 18 years, with the latest figure at $48.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 137.65% year-over-year to $48.7 million; the trailing twelve-month figure through Mar 2026 stood at $643.3 million (up 830.12% YoY), and the FY2025 full-year result was $465.4 million, up 1192.73% from the prior year.
• Free Cash Flow for Q1 2026 stood at $48.7 million, down from $140.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $342.3 million in Q3 2023, with the low at -$180.4 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$1.9 million across 5 years, with a median of -$74.9 million in 2023.
• Annual changes were most pronounced in 2024 — Free Cash Flow slumped 130.04% — and 2025, when it jumped 1399.9%.
• Alnylam Pharmaceuticals' Free Cash Flow stood at -$86.8 million in 2022, then jumped by 48.02% to -$45.1 million in 2023, then tumbled by 130.04% to -$103.8 million in 2024, then soared by 235.19% to $140.3 million in 2025, then slumped by 65.3% to $48.7 million in 2026.
• The last three Free Cash Flow figures came in at $48.7 million (Q1 2026), $140.3 million (Q4 2025), and $293.8 million (Q3 2025), per Business Quant data.